Journal: Journal of Pharmaceutical Analysis

Article Title: Crebanine protects against ovariectomy-induced bone loss by targeting Sirt1 to interfere with NF-κB acetylation and ROS activity

doi: 10.1016/j.jpha.2025.101426

Figure Lengend Snippet: Crebanine (Cre) prevents ovariectomy (OVX)-induced bone loss. (A) Schematic illustration of the experimental design evaluating Cre's therapeutic efficacy in vivo . (B) Representative micro-computed tomography (CT) images of distal femoral structures in each treatment group. (C–G) Quantitative measurements of bone microarchitecture parameters including bone parameters including bone volume/tissue volume (BV/TV) (C), trabecular number (Tb.N) (D), trabecular separation (Tb.Sp) (E), trabecular thickness (Tb.Th) (F), and bone mineral density (BMD) (G) of five groups ( n = 6) by CTAn software. (H) Representative hematoxylin and eosin (H&E) staining images of distal femurs sections in each group. (I) Quantitative analyses of BV/TV ( n = 6). Data represent means ± standard error of the mean (SEM). Statistical significance was determined by one-way analysis of variance (ANOVA) with Tukey's multiple comparison test. ∗ P < 0.05 and ∗∗ P < 0.01. Aln: alendronate; TRAP: tartrate-resistant acid phosphatase; ELISA: enzyme-linked immunosorbent assay; β-CTx: type I collagen cross-linked C-terminal telopeptide; IHC: immunohistochemistry; Sirt1: sirtuin 1.

Article Snippet: Cre (C 20 H 21 NO 4 , purity ≥ 99.54%, HY-N2255) and alendronate (Aln) (C 4 H 12 NNaO 7 P 2, purity ≥ 98.0%, HY-108685) were commercially sourced from MedChemExpress (Monmouth Junction, NJ, USA).

Techniques: Drug discovery, In Vivo, Micro-CT, Software, Staining, Comparison, Enzyme-linked Immunosorbent Assay, Immunohistochemistry

Journal: Nanomedicine

Article Title: Bone-targeted cabazitaxel nanoparticles for metastatic prostate cancer skeletal lesions and pain

doi: 10.2217/nnm-2017-0190

Figure Lengend Snippet: (A) Schematic illustrating nanoparticle (NP) synthesis through water-in-oil-in-water double emulsion solvent evaporation technique followed by activation of nanoparticle with alendronate for bone targeting. (B) Size (red) and polydispersity index (blue) of nontargeted NP versus targeted NP. Mean ± SEM (n = 3). ** p-value < 0.005. (C) Mean encapsulation efficiency of drug within nanoparticle at various initial concentrations of cabazitaxel in the NP formulation as a percentage of total weight of polymer and drug. (D) Release kinetics of cabazitaxel from NP at time points (1, 5, 8, 12, 24, 72 h). (Inset) magnification of time points (1, 5, 8 h). Mean ± SEM (n = 3). (e) Scanning electron microscopy images of nontargeted NP and targeted NP.

Article Snippet: Lyophilized nanoparticles and alendronate (Santa Cruz Biotechnology, CA, USA) were used at a 1:1 w/w ratio and suspended in 1 ml of PBS at room temperature for 15 min separately.

Techniques: Double Emulsion, Solvent, Evaporation, Activation Assay, Encapsulation, Formulation, Polymer, Electron Microscopy

Journal: Experimental and Therapeutic Medicine

Article Title: Green tea extract synergistically enhances the effectiveness of an antiresorptive drug on management of osteoporosis induced by ovariectomy in a rat model

doi: 10.3892/etm.2021.9759

Figure Lengend Snippet: Grouping of the animals in the present study (n=8/group).

Article Snippet: Alendronate sodium and raloxifene hydrochloride were purchased from Merck KGaA and Eli Lilly and Company, respectively.

Techniques:

Journal: Experimental and Therapeutic Medicine

Article Title: Green tea extract synergistically enhances the effectiveness of an antiresorptive drug on management of osteoporosis induced by ovariectomy in a rat model

doi: 10.3892/etm.2021.9759

Figure Lengend Snippet: Changes of total BMD at different regions of rats co-treated with GTE and antiresorptive drugs. Mean of percentage changes from baseline (Week 0) of the total BMD at lumbar spine, proximal tibia and distal femur co-treated with (A) A and (B) R. The error bar represents the ±SD. Two-way ANOVA followed by Bonferroni's correction. * P<0.05; ** P<0.01; *** P<0.001. BMD, bone mineral density; GTE, green tea extract; OVC, ovariectomized; ns, not significant; L, low dose; H, high dose; A, alendronate; R, raloxifene.

Article Snippet: Alendronate sodium and raloxifene hydrochloride were purchased from Merck KGaA and Eli Lilly and Company, respectively.

Techniques:

Journal: Experimental and Therapeutic Medicine

Article Title: Green tea extract synergistically enhances the effectiveness of an antiresorptive drug on management of osteoporosis induced by ovariectomy in a rat model

doi: 10.3892/etm.2021.9759

Figure Lengend Snippet: Difference in microarchitectural properties at the distal femur of rats co-treated with GTE and antiresorptive drugs. Mean of trabecular bone volume (BV/TV), trabecular number (Tb.N), trabecular thickness (Tb.Th), and trabecular separation (Tb.Sp) after 4 weeks of co-treatment with (A) A and (B) R. The error bar represents the + SD. * P<0.05; ** P<0.01; *** P<0.001 vs. OVX without treatment. GTE, green tea extract; OVX, ovariectomized; BV/TV, trabecular bone volume; Tb.N, trabecular number; Tb.Th, trabecular thickness; Tb.Sp, trabecular separation; L, low dose; H, high dose; A, alendronate; R, raloxifene.

Article Snippet: Alendronate sodium and raloxifene hydrochloride were purchased from Merck KGaA and Eli Lilly and Company, respectively.

Techniques:

Journal: Experimental and Therapeutic Medicine

Article Title: Green tea extract synergistically enhances the effectiveness of an antiresorptive drug on management of osteoporosis induced by ovariectomy in a rat model

doi: 10.3892/etm.2021.9759

Figure Lengend Snippet: Difference in the concentration of bone turnover markers in the serum of rats treated with GTE and/or combinations of A. Mean of CTX, OC and TRAcP 5b concentration after 4 weeks of treatment with GTE and/or A. Error bar represents the + SD. * P<0.05; ** P<0.01; *** P<0.001 vs. OVX without treatment. GTE, green tea extract; OVX, ovariectomized; L, low dose; H, high dose; A, alendronate; OC, osteocalcin CTX, C-terminal telopeptide; TRAcP 5b, tartrate-resistant acid phosphatase 5b.

Article Snippet: Alendronate sodium and raloxifene hydrochloride were purchased from Merck KGaA and Eli Lilly and Company, respectively.

Techniques: Concentration Assay

Journal: Pharmacy and Therapeutics

Article Title: Osteoporosis: A Review of Treatment Options

doi:

Figure Lengend Snippet: Food and Drug Administration-Approved Indications for Osteoporosis Treatments 42 – 46 , 49 – 51 , 71 , 75 , 78 , 84 – 86 , 88 , 89 , 93 , 97

Article Snippet: 33 table ft1 table-wrap mode="anchored" t5 caption a7 Drug (Brand, Manufacturer) Treatment of PMO Prevention of PMO Treatment (men) Treatment of GIO Prevention of GIO Alendronate (Fosamax, Merck) x x x x x Alendronate/cholecalciferol (Fosamax Plus D, Merck) x x Alendronate effervescent (Binosto, Mission Pharmacal) x x Risedronate IR (Actonel, Warner Chilcott) x x x x x Risedronate DR (Atelvia, Warner Chilcott) x Ibandronate injection (Boniva, Genentech) x Ibandronate tablets (Boniva, Genentech) x x Zoledronic acid (Reclast, Novartis) x x x x x Denosumab (Prolia, Amgen) a x x Raloxifene (Evista, Lilly USA) x x Conjugated estrogens/bazedoxifene (Duavee, Pfizer) x Teriparatide (Forteo, Lilly USA) b x c x Abaloparatide (Tymlos, Radius Health) x Calcitonin-salmon d x Open in a separate window a Also indicated to increase bone mass in women and men at high risk of fracture without osteoporosis. b Treatment only for those at high risk of fracture. c Increases bone mass in men with primary or hypogonadal osteoporosis at high risk of fracture. d Miacalcin injection (Novartis) is indicated for the treatment of PMO in women more than five years postmenopause when alternative treatments are not suitable.

Techniques: Injection

Journal: Pharmacy and Therapeutics

Article Title: Osteoporosis: A Review of Treatment Options

doi:

Figure Lengend Snippet: Dose Recommendations for Bisphosphonates 42 , 43 , 45 , 56 , 48 , 49

Article Snippet: 33 table ft1 table-wrap mode="anchored" t5 caption a7 Drug (Brand, Manufacturer) Treatment of PMO Prevention of PMO Treatment (men) Treatment of GIO Prevention of GIO Alendronate (Fosamax, Merck) x x x x x Alendronate/cholecalciferol (Fosamax Plus D, Merck) x x Alendronate effervescent (Binosto, Mission Pharmacal) x x Risedronate IR (Actonel, Warner Chilcott) x x x x x Risedronate DR (Atelvia, Warner Chilcott) x Ibandronate injection (Boniva, Genentech) x Ibandronate tablets (Boniva, Genentech) x x Zoledronic acid (Reclast, Novartis) x x x x x Denosumab (Prolia, Amgen) a x x Raloxifene (Evista, Lilly USA) x x Conjugated estrogens/bazedoxifene (Duavee, Pfizer) x Teriparatide (Forteo, Lilly USA) b x c x Abaloparatide (Tymlos, Radius Health) x Calcitonin-salmon d x Open in a separate window a Also indicated to increase bone mass in women and men at high risk of fracture without osteoporosis. b Treatment only for those at high risk of fracture. c Increases bone mass in men with primary or hypogonadal osteoporosis at high risk of fracture. d Miacalcin injection (Novartis) is indicated for the treatment of PMO in women more than five years postmenopause when alternative treatments are not suitable.

Techniques:

Journal: Pharmacy and Therapeutics

Article Title: Osteoporosis: A Review of Treatment Options

doi:

Figure Lengend Snippet: AWPs of Selected Osteoporosis Medications 110

Article Snippet: 33 table ft1 table-wrap mode="anchored" t5 caption a7 Drug (Brand, Manufacturer) Treatment of PMO Prevention of PMO Treatment (men) Treatment of GIO Prevention of GIO Alendronate (Fosamax, Merck) x x x x x Alendronate/cholecalciferol (Fosamax Plus D, Merck) x x Alendronate effervescent (Binosto, Mission Pharmacal) x x Risedronate IR (Actonel, Warner Chilcott) x x x x x Risedronate DR (Atelvia, Warner Chilcott) x Ibandronate injection (Boniva, Genentech) x Ibandronate tablets (Boniva, Genentech) x x Zoledronic acid (Reclast, Novartis) x x x x x Denosumab (Prolia, Amgen) a x x Raloxifene (Evista, Lilly USA) x x Conjugated estrogens/bazedoxifene (Duavee, Pfizer) x Teriparatide (Forteo, Lilly USA) b x c x Abaloparatide (Tymlos, Radius Health) x Calcitonin-salmon d x Open in a separate window a Also indicated to increase bone mass in women and men at high risk of fracture without osteoporosis. b Treatment only for those at high risk of fracture. c Increases bone mass in men with primary or hypogonadal osteoporosis at high risk of fracture. d Miacalcin injection (Novartis) is indicated for the treatment of PMO in women more than five years postmenopause when alternative treatments are not suitable.

Techniques: